News

2015

• September 2015 - i3 Pharmaceuticals was formed with strong capital backing from private investors. 
• October 2015 – Leased laboratory space in Plymouth Meeting, PA.

2016

• January 2016 - Acquired a 150,000 square feet building in Warminster, PA.
• December 2016 - Moved into the newly constructed facility with state of the art research and analytical laboratories, pilot & commercial manufacturing plants and warehouse.

2018

• June 2018 – Filed first ANDA with the US FDA for a product for which there was formerly no generic alternative available.
• December 2018 - Successful FDA Prior Approval and GMP inspection.

2020

• April 2020 - Gained FDA ANDA approval for Ramelteon 8mg tablets.
• September 2020 - Gained FDA ANDA approval for Chlorzoxazone 375 and 750mg tablets.

2021

• June 2021 - Successful FDA full, virtual GMP inspection.
• September 2021 - Gained FDA ANDA approval for Selegiline HCl 5mg tablets.

2022

• February 2022 - Launched Selegiline HCl 5mg tablets into US Market. First product commercialized in the i3 label.
• October 2022 - Launched Ranolazine 500mg and 1000mg extended-release tablets into US Market.